Skip to content
Clinical Trials – home

Centre Hospitalier Le Mans

Research site

France 194 Avenue Rubillard, 72037 Le Mans, France

  • 82 trials recruiting
  • Non-small cell lung cancer · Non-small cell lung cancer stage IV · Chronic lymphocytic leukaemia
  • Adults and children

About Specializations

Centre Hospitalier Le Mans in Le Mans, France specialises in clinical trials of conditions such as Non-small cell lung cancer, Non-small cell lung cancer stage IV, Chronic lymphocytic leukaemia, Hidradenitis, and other specialisations. This site conducts important research.

Main research areas of the site

Pneumology and Respiratory Disease Research at Centre Hospitalier Le Mans

This site is active in respiratory medicine and related circulatory and respiratory physiological phenomena, with studies focused on conditions such as non-small cell lung cancer, small cell lung cancer, pulmonary hypertension, acute respiratory failure, and Mycobacterium xenopi pulmonary infection. The trials are designed to test new treatments, improve symptom control, and evaluate better ways to manage advanced breathing-related disease.

  • Lung cancer studies in NSCLC, extensive-stage small cell lung cancer, and pleural mesothelioma, often comparing newer treatment combinations with current standards
  • Respiratory infection research, including Mycobacterium xenopi pulmonary infection, aimed at improving infection control and treatment response
  • Critical care and breathing support work on acute respiratory failure and high-flow nasal oxygen therapy, with a focus on safer and more effective respiratory management

Overall, the Le Mans hospital contributes to a broad respiratory portfolio that links cancer care, infection treatment, and supportive care for patients with serious lung conditions.

Oncology and Hematology Trials

Another major area of research at the site is cancer and blood disorders, spanning neoplasms and hemic and lymphatic diseases. Current studies include prostate cancer, melanoma, acute leukemia, myelodysplastic syndrome, and several lymphomas. These trials mainly aim to assess whether new therapies can improve survival, delay relapse, or better control advanced disease.

  • Prostate cancer research in both localized and metastatic disease, with attention to disease control and long-term outcomes
  • Lymphoma studies in follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma
  • Leukemia and myelodysplastic syndrome trials exploring new options for relapsed or hard-to-treat blood cancers

These studies reflect a strong focus on testing more effective systemic treatments for patients with complex hematologic malignancies and advanced solid tumors.

Autoimmune, Inflammatory, and Skin Disease Studies

The site also conducts trials in immune system diseases, skin and connective tissue diseases, and musculoskeletal diseases. Research includes atopic dermatitis, hidradenitis suppurativa, giant cell arteritis, polymyalgia rheumatica, Sjögren’s syndrome, and rotator cuff tendinopathy. The purpose of these trials is to find better ways to reduce inflammation, improve daily function, and maintain disease control over time.

  • Atopic dermatitis and hidradenitis suppurativa studies aimed at improving skin symptom control
  • Rheumatology research in giant cell arteritis and polymyalgia rheumatica, focused on sustained remission and relapse prevention
  • Autoimmune disease trials in Sjögren’s syndrome and related inflammatory conditions

At Centre Hospitalier Le Mans, these projects show a clear interest in chronic inflammatory diseases that affect comfort, mobility, and quality of life.

Metabolic, Cardiovascular, and Other Internal Medicine Research

This research portfolio extends into cardiovascular diseases, nutritional and metabolic diseases, digestive system diseases, and selected pathological conditions. Studies include gout with hyperuricemia, prevention of ischemic stroke, and other conditions where treatment aims to lower risk, improve long-term outcomes, or reduce complications after serious illness.

  • Stroke prevention research in patients after acute ischemic stroke or high-risk transient ischemic attack
  • Gout and hyperuricemia studies focused on better uric acid control
  • Cardiovascular and metabolic trials addressing risk reduction and chronic disease management

These studies add breadth to the site’s clinical trial activity, showing that the hospital addresses both specialist respiratory care and broader internal medicine needs.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
194 Avenue Rubillard72037 Le MansFrance
Recruiting now
82 trials
Conditions studied
120

More sites in Le MansFrance

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

204 clinical trials

Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan Hydrochloride
  • Sponsor:Zai Lab (US) LLC

Eczema nummular

Recruiting

A study to evaluate the effectiveness and safety of lebrikizumab in adults with nummular eczema who do not respond well to topical corticosteroids.

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Dermatomyositis+1

Recruiting

Study on Anifrolumab for Adults with Polymyositis or Dermatomyositis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Study on RVU120 and Venetoclax for Patients with Acute Myeloid Leukemia After Previous Treatment Failure

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax
  • Sponsor:Ryvu Therapeutics S.A.

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Phase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma Patients Receiving JNJ-79635322 and Human Normal Immunoglobulin (IV)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Janssen Cilag International

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.